BR112017014615A2 - proteínas de fusão de multi-direcionamento e seus usos - Google Patents

proteínas de fusão de multi-direcionamento e seus usos

Info

Publication number
BR112017014615A2
BR112017014615A2 BR112017014615A BR112017014615A BR112017014615A2 BR 112017014615 A2 BR112017014615 A2 BR 112017014615A2 BR 112017014615 A BR112017014615 A BR 112017014615A BR 112017014615 A BR112017014615 A BR 112017014615A BR 112017014615 A2 BR112017014615 A2 BR 112017014615A2
Authority
BR
Brazil
Prior art keywords
fusion proteins
targeting fusion
binding moiety
edema
inflammation
Prior art date
Application number
BR112017014615A
Other languages
English (en)
Inventor
Hsu Ching-Hsuan
Chen Huang-Tsu
Her Jeng-Horng
Leou Jiun-Shyang
Zen Kevin
Wu Pai-Tzu
Original Assignee
Allgenesis Biotherapeutics Inc
Ap Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allgenesis Biotherapeutics Inc, Ap Biosciences Inc filed Critical Allgenesis Biotherapeutics Inc
Publication of BR112017014615A2 publication Critical patent/BR112017014615A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Epidemiology (AREA)

Abstract

proteínas de fusão contendo uma porção de ligação de pdgf, uma porção de ligação de vegf, e uma região de anticorpo de fc são descritas. também são descritos ácidos nucleicos que codificam as proteínas de fusão, composições compreendendo as proteínas de fusão, e métodos de uso como proteínas de fusão para o tratamento ou para a prevenção de condições clínicas caracterizadas por angiogênese anormal, tal como permeabilidade vascular, edema ou inflamação.
BR112017014615A 2015-03-11 2016-03-10 proteínas de fusão de multi-direcionamento e seus usos BR112017014615A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562131261P 2015-03-11 2015-03-11
PCT/US2016/021762 WO2016145189A1 (en) 2015-03-11 2016-03-10 Fusion protein comprising a ligand binding domain of vegf and pdgf

Publications (1)

Publication Number Publication Date
BR112017014615A2 true BR112017014615A2 (pt) 2018-02-06

Family

ID=55642865

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014615A BR112017014615A2 (pt) 2015-03-11 2016-03-10 proteínas de fusão de multi-direcionamento e seus usos

Country Status (13)

Country Link
US (1) US11299531B2 (pt)
EP (1) EP3268386B1 (pt)
JP (1) JP6649393B2 (pt)
KR (1) KR20170117107A (pt)
CN (1) CN107108757B (pt)
AU (1) AU2016229053B2 (pt)
BR (1) BR112017014615A2 (pt)
CA (1) CA2970384A1 (pt)
ES (1) ES2873379T3 (pt)
MX (1) MX2017008643A (pt)
SG (1) SG11201705271YA (pt)
TW (1) TWI675844B (pt)
WO (1) WO2016145189A1 (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
EP3313426B1 (en) 2015-06-28 2020-04-29 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
TWI723247B (zh) * 2017-02-06 2021-04-01 中央研究院 重組蛋白及其用途
CN111406071B (zh) * 2017-11-16 2024-01-16 成都硕德药业有限公司 Pas化的vegfr/pdgfr融合蛋白及其在治疗中的用途
EP3710483A4 (en) * 2017-11-16 2021-10-20 XL-protein GmbH PASYLATED VEGFR / PDGFR FUSION PROTEINS AND THEIR USE IN THERAPY
SG11202005290QA (en) * 2018-02-28 2020-07-29 Ap Biosciences Inc Bifunctional proteins combining checkpoint blockade for targeted therapy
CN112203679A (zh) 2018-03-02 2021-01-08 科达制药股份有限公司 Il-6抗体及其融合构建体和缀合物
US11518819B2 (en) * 2018-08-17 2022-12-06 Trican Biotechnology Co., Ltd Anti-angiogenesis fusion protein and uses thereof
CN112552410A (zh) * 2019-09-26 2021-03-26 三生国健药业（上海）股份有限公司 一种抗体融合蛋白及其制法和在抗肿瘤中的应用
CN114786731A (zh) 2019-10-10 2022-07-22 科达制药股份有限公司 治疗眼部病症的方法
CN112834753A (zh) * 2019-11-22 2021-05-25 北京泰德制药股份有限公司 一种融合蛋白体外生物学活性的检测方法
US20230137756A1 (en) * 2020-03-30 2023-05-04 The Wistar Institute Of Anatomy And Biology Synthetic Soluble Receptor Mimics and Methods of Use for Treatment of COVID-19
CN116162148A (zh) * 2021-11-24 2023-05-26 苏州光度生物科技有限公司 多特异性配体结合分子及其应用
CN116836281A (zh) * 2022-03-25 2023-10-03 英诺湖医药(杭州)有限公司 B7h3抗体及包含其的双功能抗体
US11723955B1 (en) * 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003900481A0 (en) * 2003-02-05 2003-02-20 Queensland University Of Technology Synthetic modulators of cell migration and growth
US20060234347A1 (en) 2005-04-13 2006-10-19 Harding Thomas C Targeting multiple angiogenic pathways for cancer therapy using soluble tyrosine kinase receptors
CN102311502B (zh) 2010-07-10 2013-12-25 成都康弘生物科技有限公司 一种抑制血管新生或生长的融合蛋白及其医疗应用
ES2933558T3 (es) 2013-03-13 2023-02-10 Genzyme Corp Proteínas de fusión que comprenden porciones de unión a PDGF y VEGF y métodos de uso de las mismas
WO2015109898A1 (zh) * 2014-01-24 2015-07-30 上海恒瑞医药有限公司 VEGF与PDGFRβ双特异性融合蛋白及其用途
EP3313426B1 (en) * 2015-06-28 2020-04-29 Allgenesis Biotherapeutics Inc. Fusion proteins for inhibiting angiogenesis

Also Published As

Publication number Publication date
TW201643186A (zh) 2016-12-16
JP6649393B2 (ja) 2020-02-19
WO2016145189A8 (en) 2017-09-08
AU2016229053A1 (en) 2017-07-06
WO2016145189A1 (en) 2016-09-15
MX2017008643A (es) 2018-04-26
EP3268386B1 (en) 2021-03-31
KR20170117107A (ko) 2017-10-20
AU2016229053B2 (en) 2018-07-12
CN107108757A (zh) 2017-08-29
AU2016229053A8 (en) 2017-09-28
ES2873379T3 (es) 2021-11-03
JP2018512120A (ja) 2018-05-17
SG11201705271YA (en) 2017-07-28
US20170369552A1 (en) 2017-12-28
CN107108757B (zh) 2021-10-19
US11299531B2 (en) 2022-04-12
TWI675844B (zh) 2019-11-01
CA2970384A1 (en) 2016-09-15
EP3268386A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
BR112017014615A2 (pt) proteínas de fusão de multi-direcionamento e seus usos
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
CO2019006485A2 (es) Anticuerpos y metodos de su utilizacion
EA201891420A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
CO2017009954A2 (es) Dominios diseñados con repeticiones de anquirina con especificidad de unión para la seroalbúmina
MY192226A (en) Anti-tigit antigen-binding proteins and methods of use thereof
CL2019000729A1 (es) Proteínas de unión recombinantes y sus usos.
BR112018006237A2 (pt) proteínas de ligação a pd-1 e métodos de uso das mesmas
PH12018500252A1 (en) Factor ix fusion protiens and methods of making and using same
EA201791253A1 (ru) Антитела к миостатину, полипептиды, содержащие варианты fc-областей, и способы их применения
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
ECSP18096095A (es) Anticuerpos a la alfa-sinucleína y usos de los mismos
BR112016029318A2 (pt) tratamento de mielomas
BR112018010673A8 (pt) moléculas de anticorpo para april e seus usos
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
BR112019012796A2 (pt) proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas
BR112016016916A8 (pt) uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae)
BR112017014258A2 (pt) anticorpos anti-cd47 e usos dos mesmos
EA201990017A1 (ru) Антитела к миостатину и способы их применения
WO2015109124A3 (en) Immunomodulatory agents
BR112015031073A2 (pt) inibidores bicíclicos de bromodomínio
SG10201909716RA (en) Modified j-chain
BR112017013568A2 (pt) compostos bicíclicos fundidos para o tratamento de doenças
AR092737A1 (es) Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf, uso y metodo de tratamiento del cancer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements